Grifols (NASDAQ:GRFS) Shares Down 3.7% – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS)’s share price traded down 3.7% on Friday . The company traded as low as $7.16 and last traded at $7.20. 616,128 shares changed hands during trading, a decline of 10% from the average session volume of 683,670 shares. The stock had previously closed at $7.47.

Analysts Set New Price Targets

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Price Performance

The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The business’s 50-day moving average is $7.71 and its 200-day moving average is $8.20.

Institutional Investors Weigh In On Grifols

A number of institutional investors have recently modified their holdings of GRFS. R Squared Ltd purchased a new stake in shares of Grifols during the 4th quarter valued at about $28,000. GAMMA Investing LLC increased its position in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 1,135 shares during the last quarter. Signaturefd LLC boosted its position in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares during the last quarter. Blue Trust Inc. grew its position in shares of Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 4,970 shares during the period. Finally, AQR Capital Management LLC purchased a new position in Grifols during the second quarter valued at $89,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.